Rapport Therapeutics, Inc.
RAPP
$11.36
-$0.025-0.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -78.31M | -71.85M | -63.02M | -51.31M | -34.79M |
| Total Depreciation and Amortization | 839.00K | 632.00K | 436.00K | 249.00K | 112.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.06M | 12.29M | 11.89M | 11.15M | 4.84M |
| Change in Net Operating Assets | -2.42M | -1.81M | 948.00K | -83.00K | 2.65M |
| Cash from Operations | -64.83M | -60.74M | -49.75M | -40.00M | -27.18M |
| Capital Expenditure | -2.41M | -3.62M | -3.53M | -2.65M | -1.64M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -167.74M | -277.12M | -224.22M | -118.08M | -77.22M |
| Cash from Investing | -170.14M | -280.73M | -227.74M | -120.73M | -78.86M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 159.11M | 159.10M | 159.10M | 30.00K | 54.00K |
| Repurchase of Common Stock | -1.39M | -1.39M | -4.00K | -4.00K | -4.00K |
| Issuance of Preferred Stock | 63.94M | 63.94M | 149.25M | 149.25M | 145.31M |
| Repurchase of Preferred Stock | -29.00K | -35.00K | -35.00K | -86.00K | -86.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -134.00K | -76.00K | -399.00K | -134.00K |
| Cash from Financing | 221.63M | 221.48M | 308.23M | 148.79M | 145.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.34M | -119.99M | 30.74M | -11.93M | 39.10M |